Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It was further observed that pro-inflammatory cytokine like, TNF-α (Tumor Necrosis Factor-α) can antagonize TGF-β2-induced response by down-regulating autophagy, increasing ROS levels and thus inhibiting EMT in HCC cells.
|
29464083 |
2018 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Deletion of key genes within the tumor necrosis factor (TNF) signaling, interferon-γ (IFN-γ) signaling, and antigen presentation pathways provided protection of tumor cells from CD8<sup>+</sup> T cell-mediated killing and blunted antitumor immune responses in vivo.
|
29776993 |
2018 |
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Serum and peritoneal levels of vascular endothelial growth factor (VEGF), total antioxidant activity (TAC) and tumor necrosis (TNF)-α were measured.
|
30545536 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Autocrine tumor necrosis factor (TNF) signaling in the absence of TAK1 induced spontaneous RIPK1-dependent NLRP3 inflammasome activation and cell death.
|
29500178 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
IL-1β (Interleukin-1β) and TNF-α (Tumor Necrosis Factor-α) Impact Abdominal Aortic Aneurysm Formation by Differential Effects on Macrophage Polarization.
|
29217508 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The concentrations of TNF-α (Tumor Necrosis Factor-α), IL-1β (Interleukin-1β), IL-6 and PGE-2 (Prostaglandin-E2) were evaluated using ELISA.
|
30014878 |
2018 |
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The main mechanism implicated in these beneficial effects were the inhibition of the downregulation of synaptophysin and its anti-inflammatory properties by means of preventing the upregulation of NF-κB and TNF-α (Tumor Necrosis Factor α) induced by diabetes.
|
30127248 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The top four enriched pathways were the tumor necrosis factor (TNF) signaling pathway, P53 signaling pathway, neuroactive ligand‑receptor interaction and the forkhead box O signaling pathway.
|
29845294 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The therapeutic response to biologics supports the pivotal role of the tumour necrosis alpha (TNF-?)/ interleukin (IL)-23/IL-17/IL-22 axis in the pathogenesis of these disorders.
|
28967976 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LPS-mediated induction of Ccl17 in the hippocampus was dependent on local tumor necrosis factor (TNF) signaling, whereas upregulation of Ccl22 required granulocyte-macrophage colony-stimulating factor (GM-CSF).
|
30277599 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Notably, the transforming growth factor (TGF)‑β, mitogen‑activated protein kinase (MAPK) and tumor necrosis factor (TNF) signaling pathways were preferentially overrepresented in the Mg and LIPUS combination group, which was subsequently confirmed by reverse transcription‑quantitative polymerase chain reaction.
|
29767241 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of tumor necrosis factor (TNF) signaling pathway which regulates the transcription factor Nuclear Factor κB (NF-κB) using this method identifies two types of incorrect cell decisions called false alarm and miss.
|
28379950 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that these proteins mainly were involved in the process of cytokine-cytokine receptor interaction, transforming growth factor-β (TGF-β) signaling pathway, pathways in cancer, tumor necrosis factor (TNF) signaling pathway, and mitogen-activated protein kinase (MAPK) signaling pathway.
|
29344174 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Signaling pathway analysis revealed that these DEGs were mainly involved in apoptosis, hypoxia‑inducible factor (HIF) 1a pathway, innate immune system, tumor necrosis factor (TNF) signaling pathway, cytokine‑cytokine receptor interaction, and other signal transduction pathways.
|
28944843 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
3xTg-AD mice had an increased pro-inflammatory response characterised by the production of pro-inflammatory mediators such as tumour necrosis TNF-α, IL-6, CCL5 and CXCL-1, as well as an increase in immune cell infiltration to the sites of infection.
|
28284226 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PubMed literature searches were conducted using combinations of search terms including ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, switch/switching, drug survival, and TNF/tumor necrosis factor to identify published articles with data on outcomes related to switching biologic therapies in patients with axSpA.
|
28551170 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor necrosis factor (TNF) signaling is required for inflammatory nociceptive (pain) sensitization in Drosophila and vertebrates.
|
28492538 |
2017 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Chondrocytes from normal joint cartilage were cultured <i>in vitro</i> for interleukin 6 (IL6) or tumor necrosis factor (TNF) treatment and si-NR4A1 transfection, after which the possible mechanism involving NR4A1 was analyzed.
|
28337303 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor necrosis factor-α (TNF-α)-induced protein 8-like-2 (TNFAIP8L2 or TIPE2), a member of the tumor necrosis TNFAIP8 family, was found to be involved in the development and progression of several tumors.
|
28081733 |
2017 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Interferon (IFN)γ release was evaluated by ELISA whereas cytokine profile [IFNγ, tumor necrosis (TNF)α, interleukin (IL)2] and phenotype (CD45RA, CCR7) by flow cytometry.
|
28837654 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In mouse monocytes, the lipopolysaccharide- (LPS-) induced tumor necrosis-<i>α</i> (TNF-<i>α</i>) synthesis was significantly inhibited by HNK and the MCP : HNK combination in a dose-dependent manner and synergistic effects were clearly demonstrated with the combination on TNF-<i>α</i> inhibition.
|
28900464 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) with regards to symptom management and mucosal healing.
|
28373759 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The tumor necrosis factor (TNF) signalling pathway was the most involved and preferentially inhibited by the hBCP material.
|
28942129 |
2017 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TNF-α inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF-treated subjects, but was also associated with elevated TNF-α and IL-17 in etanercept-treated subjects.
|
26934060 |
2016 |
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These humoral factors can generally be divided into those which, like RANKL, are tumour necrosis family (TNF) superfamily members and those which are not; the former include TNFα lymphotoxin exhibiting inducible expression and competing with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes (LIGHT), a proliferation inducing ligand (APRIL) and B cell activating factor (BAFF); the latter include transforming growth factor beta (TGF-β), interleukin-6 (IL-6), IL-8, IL-11, nerve growth factor (NGF), insulin-like growth factor-I (IGF-I) and IGF-II.
|
26578261 |
2016 |